Key result
Vascular targeting agents offer a promising strategy to selectively block tumor blood flow by targeting endothelial cell markers, basement membrane components, and tumor cell surface antigens.
Vascular targeting agents represent a promising therapeutic approach to selectively destroy tumor vasculature by exploiting specific endothelial and basement membrane markers.
Vascular targeting merits clinical evaluation in oncology; leaves open optimal marker selection and human efficacy trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Brekken et al. (2002) conducted a review in Solid tumors. Vascular targeting agents was evaluated. Vascular targeting agents offer a promising strategy to selectively block tumor blood flow by targeting endothelial cell markers, basement membrane components, and tumor cell surface antigens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: